Individuals aged >1 8 years with >2 CHC claims between 2001–2012, dual (ribavirin [RBV]+interferon [IFN]) or triple (RBV+IFN+protease inhibitor) HCV therapy, and a post-treatment HCV RNA check details test were included. Patients with prior treatment were excluded. All had continuous health plan enrollment for ≧12 months before beginning and after ending treatment. Patients with a detectable HCV RNA result after ending treatment were considered Detected; those with only undetectable results (>1 result ≧12 weeks post-treatment) were grouped as Undetected. Total costs (medical+pharmacy) represent 2012US$. Chi-square and t-tests were used for statistical analyses.

Results: Of the 1724 CHC patients identified, 1063 were considered Undetected (61.7%) while 661 were grouped as Detected. The majority click here (98.7%) received dual therapy. Mean±SD treatment duration was 37.8±14.5 weeks in the Undetected

and 30.1 ±18.3 weeks in the Detected group (p<0.001), and post-treatment full follow-up was 3.8±2.4 years in the Undetected and 3.6±2.2 years in the Detected group (p=0.09). The Detected group was older (mean age=50.4 vs 48.6 years, respectively), had more males (67.0% vs 58.6%), and had more patients with baseline moderate or severe liver disease (as defined by Charlson comorbidity index) (7.0% vs 2.1%) than the Undetected group (p<0.001 for all). Per subject per year Lck (PSPY) HRU are below (Table). Mean±SD PSPY all-cause total costs for the Undetected group were $9873±$30654 in the 12 month follow-up (vs $ 10681 ±$21353 Detected; p=0.519) and $ 101 73±$24434

in the full follow-up period (vs $15287±$34732 Detected; p<0.001). HCV-related total costs for the Undetected group in the 12-month and full follow-up periods were $1294±$1 1638 (vs $2749±$ 14295 Detected; p=0.028) and $922±$7707 (vs $5027±$24884 Detected; p<0.001), respectively. Conclusion: This analysis of longitudinal claims data alongside lab results provides evidence of lower costs among CHC patients achieving undetectable HCV RNA levels after HCV treatment as compared with those with detectable levels.   12-month Follow-up   Full Follow-up   *p<0.05; tp<0.001; NS=p>0.05 Disclosures: J. B. Forlenza – Employment: Janssen Scientific Affairs, LLC; Stock Shareholder: Janssen Scientific Affairs, LLC Ami R. Buikema – Employment: Optum Neeta Tandon – Employment: Johnson & Johnson Co Joyce C. LaMori – Employment: Janssen Scientific Affairs; Stock Shareholder: Johnson & Johnson Background & Aims: Routine screening for unrelated cancers has been shown to predict earlier stage of diagnosis of several other cancers. No studies have investigated the association of receipt of routine non-HCC cancer screening tests with stage of diagnosis and ultimate survival in patients who develop hepatocellular carcinoma (HCC).